Genetic determinants of plasma lipoproteins

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue 11, 2007, Pages 600-609

  Pollex, Rebecca L ^a   Hegele, Robert A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NIEMANN PICK C1 LIKE 1 PROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DNA SEQUENCE; DYSLIPIDEMIA; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LABORATORY AUTOMATION; LINKAGE ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT; REVIEW; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CHOLESTEROL; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; HUMANS; LIPOPROTEINS; PHENOTYPE; TRIGLYCERIDES; VARIATION (GENETICS);

EID: 35648970136     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1005     Document Type: Review

References (73)

1. Lusis AJ et al. (2004) Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 5: 189-218
2. Dammerman M and Breslow JL (1995) Genetic basis of lipoprotein disorders. Circulation 91: 505-512
3. Talmud PJ and Humphries SE (2001) Genetic polymorphisms, lipoproteins and coronary artery disease risk. Curr Opin Lipidol 12: 405-409
4. Volcik KA et al. (2006) Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 164: 342-348
5. Boekholdt SM et al. (2005) Cholersteryl ester transfer protein TaqlB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: Individual patient meta-analysis of 13,677 subjefts. Circulation 111: 278-287
6. Brousseau ME et al. (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505-1515
7. Nissen SE et al. (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356: 1304-1316
8. Walden CC and Hegele RA (1994) Apolipoprotein E in hypedipidemia. Ann Intern Med 120: 1026-1036
9. Cohen JC et al. (1994) Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest 94: 2377-2384
10. Wang J et al. (1998) Linkage between cholesterol 7α-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J Clin Invest 101: 1283-1291
11. Guerra R et al. (1997) A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci USA 94: 4532-4537
12. Hegele RA et al. (1999) Absence of association between genetic variation in the LIPC gene promoter and plasma lipoprotains in thi6e Canadian populations. Atherosclerosis 146: 153-160
13. Hegele RA et al. (2001) Variable association between genetic variation in the CYP7 gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis 154: 579-587
14. Yuan G et al. (2006) Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 174: 1124-1129
15. Hegele RA (1997) Small genetic effects in complex diseases: A review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Clin Biochem 30: 183-188
16. Li WW et al. (1995) Common genetic variation in the promoter of the human apo Cill gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 96: 2601-2605
17. Pollex RL et al. (2006) Metabolic syndrome in. aboriginal Canadians: Prevalence and genetic associations. Atherosclerosis 184: 121-129
18. McKinney J et al. (2003) Maturity-onset diabetes of the young (MODY) mutation in type 2 diabetes and latent autoimmune diabetes of the adult. Diabetes Care 26: 3358-33591
19. Funke H (1997) Genetic determinants of high density lipoprotein levels. Curr Opin Lipidol 8: 189-196
20. Brooks-Wilson A et al. (1999) Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22 336-345
21. Cohen JC et al. (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305: 869-872
22. Abifadel M et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156
23. Cohen J et al. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37: 161-165
24. Cohen JC et al. (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: 1264-1272
25. Tall AR (2006) Protease variants, LDL, and coronary heart disease. N Engl J Med 354: 1310-1312
26. Mani A et al. (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315: 1278-1282
27. Romeo S et al. (2007) Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 39: 513-516
28. Huff MW et al. (2006) NPC1L1: Evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 26: 2433-2438
29. Wang J et al. (2005) Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin Genet 67: 175-177
30. Hegele RA et al. (2005) NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis 4: 16
31. Simon JS et al. (2005) Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 86: 648-656
32. Cohen JC et al. (2006) Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci USA 103: 1810-1815
33. Service RF (2006) Gene sequencing: The race for the $1,000 genome. Science 311: 1544-1546
34. Redon R et al. (2006) Global variation in copy number in the human genome. Nature 444: 444-454
35. Davey Smith G and Ebrahim S (2003) 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22
36. Brown MS and Goldstein JL (2006) Biomedicine: Lowering LDL - not only how low, but how long? Science 311: 1721-1723
37. Letonja M et al. (2004) Apolipoprotein E gene polymorphism effects triglycerides but not CAD risk in Caucasian women younger than 65 years. Ann Genet 47: 147-153
38. Hegele RA (1997) Candidate genes, small effects, and the prediction of atherosclerosis. Crit Rev Clin Lab Sci 34: 343-367
39. Topol EJ (2005) Simon Deck Lecture: The genomic basis of myocardial infarction. J Am Coll Cardiol 46: 1456-1465
40. Humphries SE et al. (2007) Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men. Clin Chem 53: 8-16
41. Kryukov GV et al. (2007) Most rare missense alleles are deleterious in humans: Implications for complex disease and association studies. Am J Hum Genet 80: 727-739
42. Benton JL et al. (2006) Associations between two common polymorphisms in the ABCA1 gene and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 193: 352-360
43. Klos KL et al. (2006) Consistent effects of genes involved in reverse cholesterol transport on plasma lipid and apolipoprotein levels in CARDIA participants. Arterioscler Thromb Vasc Biol 26: 1828-1836
44. Whiting BM et al. (2005) Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. Am Heart J 150: 243-250
45. Hodoglugil U et al. (2005) Common polymorphisms of ATP binding cassette transporter A1, including a functional promoter polymorphism, associated with plasma high density lipoprotein cholesterol levels in Turks. Atherosclerosis 183: 199-212
46. Qi L et al. (2006) Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. Atherosclerosis 192: 204-210
47. Hubacek JA et al. (2005) Sex-specific effect of APOAV variant (Val153>Met) on plasma levels of high-density lipoprotein cholesterol. Metabolism 54: 1632-1635
48. Hsu LA et al. (2006) Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 185: 143-149
49. Salminen M et al. (2006) Apolipoprotein E polymorphism and changes in serum lipids during a family-based counselling intervention. Public Health Nutr 9: 859-865
50. Sorli JV et al. (2006) The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European population. Clin Chim Acta 366: 196-203
51. Kolovou GD et al. (2005) Association of apolipoprotein E genotype with early onset of coronary heart disease in Greek men. Angiology 56: 663-670
52. Padmaja N et al. (2007) Common variants of Cholesteryl ester transfer protein gene and their association with lipid parameters in healthy volunteers of Tamillan population. Clin Chim Acta 375 140-146
53. Borggreve SE et al. (2006) An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: A population-based study. J Clin Endocrinol Metab 91: 3382-3388
54. Toupta Y et al. (2006) The association between high-density lipoprotein cholesterol level and cholesteryl ester transfer protein TaqlB gene polymorphism is influenced by alcohol drinking in a population-based sample. Atherosclerosis 191: 199-205
55. Frisdal E et al. (2005) Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Mol Genet 14: 2607-2618
56. Hodoglugil U et al. (2005) An interaction between the TaqlB polymorphism of cholesterol ester transfer protein and smoking is associated with changes in plasma high-density lipoprotein cholesterol levels in Turks. Clin Genet 68 118-127
57. Borggreve SE et al. (2005) The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J Clin Endocrinol Metab 90: 4198-4204
58. Lloyd DB et al. (2005) Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib. J Biol Chem 280: 14918-14922
59. Yilmaz H et al. (2005) Effects of cholesterol ester transfer protein Taq1B gene polymorphism on serum lipoprotein levels in Turkish coronary artery disease patients. Cell Biochem Funct 23: 23-28
60. McCaskie PA et al. (2006) The C-480T hepatic lipase polymorphism is associated with HDL-C but not with risk of coronary heart disease. Clin Genet 70: 114-121
61. Miljkovic-Gacic I et al. (2006) Lipoprotein subclass and particle size differences in Afro-Caribbeans, African Americans, and white Americans: Associations with hepatic lipase gene variation. Metabolism 55: 96-102
62. Zhai G et al. (2006) Association of APOA5 c.553>T polymorphism with type 2 diabetes mellitus in a Chinese population. Clin Chem Lab Med 44: 1313-1316
63. Duman BS et al. (2005) Genetic variations of the apolipoprotein B gene in Turkish patients with coronary artery disease. Ann Hum Biol 32: 620-629
64. Sivakova D et al. (2006) Apolipoprotein E polymorphism in relation to plasma lipid levels and other risk factors of atherosclerosis in two ethnic groups from Slovakia. Coll Antropol 30: 387-394
65. Mid LE et al. (2006) Relations of APOE promoter polymorphisms; to LDL cholesterol and markers of subclinical atherosclerosis in young adults. J Lipid Res 47: 1298-1306
66. Bhavani AB et al. (2005) Lipid profile and apolipoprotein E polymorphism in essential hypertension. Indian Heart J 57: 151-157
67. Shin MH et al. (2005) The effect of apolipoprotein E polymorphism on lipid levels in Korean adults. J Korean Med Sci 20: 361-366
68. Nghiem NT et al. (2004) Apolipoprotein E polymorphism in Vietnamese children and its relationship to plasma lipid and lipoprotein levels. Metabolism 53: 1517-1521
69. Zeybek U et al. (2006) Effects of cholesteryl ester transfer protein TAQ1B polymorphism in renal transplant patients. Transplant Proc 38: 1382-1384
70. Kotowski IK et al. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 78: 410-422
71. Chen SN et al. (2005) A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 45: 1611-1619
72. Hamon SC et al. (2006) Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene cluster. Hum Hered 61: 87-96
73. Davis CL et al. (2005) Genetic and environmental determinants of lipid profile in black and white youth: A study of four candidate genes. Ethn Dis 15: 568-577